NCT05532163View on ClinicalTrials.gov

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

PHASE4TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Natalizumab

Administered as specified in the treatment arm

Trial Locations (2)

53111

Neurologische Studiengesellschaft Bonn GbR, Bonn

96052

Neurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05532163 - A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Biotech Hunter | Biotech Hunter